SARS-CoV-2 Period Seroprevalence and Related Factors

SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020–March 2021

Hillsborough County, Florida, USA, October 2020-March 2021

Anna R. Giuliano; Shari Pilon-Thomas; Michael J. Schell; Martha Abrahamsen; Jessica Y. Islam; Kimberly Isaacs-Soriano; Kayoko Kennedy; Christopher W. Dukes; Junmin Whiting; Julie Rathwell; Jonathan A. Hensel; Leslie N. Mangual; Ernst Schonbrunn; Melissa Bikowitz; Dylan Grassie; Yan Yang

Disclosures

Emerging Infectious Diseases. 2022;28(3):556-563. 

In This Article

Abstract and Introduction

Abstract

Estimating the actual extent of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is challenging because virus test positivity data undercount the actual number and proportion of persons infected. SARS-CoV-2 seroprevalence is a marker of past SARS-CoV-2 infection regardless of presence or severity of symptoms and therefore is a robust biomarker of infection period prevalence. We estimated SARS-CoV-2 seroprevalence among residents of Hillsborough County, Florida, USA, to determine factors independently associated with SARS-CoV-2 antibody status overall and among asymptomatic antibody-positive persons. Among 867 participants, SARS-CoV-2 period prevalence (October 2020–March 2021) was 19.5% (asymptomatic seroprevalence was 8%). Seroprevalence was 2-fold higher than reported SARS-CoV-2 virus test positivity. Factors related to social distancing (e.g., essential worker status, not practicing social distancing, contact with a virus-positive person, and length of contact exposure time) were consistently associated with seroprevalence but did not differ by time since suspected or known infection (<6 months vs. ≥6 months).

Introduction

In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China, ultimately leading to a global pandemic.[1] Since January 2020, the United States has observed a dramatic rise in the incidence of SARS-CoV-2 infection, for which no endogenous immunity exists,[2]leading to >70.6 million cases of SARS-CoV-2 and ≈860,000 deaths in the United States.

Recommendations

processing....